← Back to Search

Monounsaturated Fatty Acid

Palmitic acid (PA) for High Cholesterol

N/A
Waitlist Available
Led By Craig L Kein, MD, PhD
Research Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

Differences in how diet fats are converted to energy could explain some of the reported differences in health effects among different classes of dietary fat (e.g. monounsaturated vs. saturated). Recently, this laboratory showed that monounsaturated fats are turned into energy more readily than saturated fats. These results may mean that if one feeds more monounsaturated fatty acids (MUFA) and less saturated fatty acids (SFA) in the diet, body fat might accumulate at a lower rate. This could affect the risk of obesity and Type 2 Diabetes. This project has two principal Specific Aims which will be assessed in healthy young adults who are fed liquid formulas containing either an approximately equal amount of MUFA and SFA (controls) or a much greater amount of MUFA and much less SFA: 1. To determine if a higher intake of MUFA and a reciprocally lower intake of SFA is associated with a higher rate of fat oxidation. We hypothesize that the rate of fat oxidation after eating will be higher in those subjects randomized to the MUFA-enriched diet compared to controls. 2. To measure energy intake required to maintain constant body weight during each diet and to measure fat-free mass and fat mass, before and after each dietary change. We hypothesize that those on the high MUFA diet will need a higher energy intake required to maintain constant body weight.

Eligible Conditions
  • High Cholesterol
  • Obesity
  • Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Palmitic acid (PA)Experimental Treatment1 Intervention
Group II: Oleic acid (OA)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oleic acid (OA)
2000
N/A
~20
Palmitic Acid (PA)
2000
N/A
~20

Find a Location

Who is running the clinical trial?

The University of Texas Medical Branch, GalvestonOTHER
252 Previous Clinical Trials
56,867 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Lead Sponsor
2,443 Previous Clinical Trials
4,331,108 Total Patients Enrolled
Craig L Kein, MD, PhDPrincipal InvestigatorThe University of Texas Medical Branch, Galveston
~1 spots leftby Nov 2025